[Instructions for the combination of PDE5 inhibitors with alpha-blockers].
The incidences of both benign prostatic hyperplasia and erectile dysfunction are increasing with aging, so the coexist of the two disease in the same patient is not rare. However, it is stumble for the clinicians to treat the patients. The problem of the combination of phosphodiesterase-5 (PDE5) inhibitors with alpha-blockers is getting more and more attraction. The article reviews the drug information of the combination of sildenafil, vardenafil and tadalafil with alpha-blockers respectively, and reports the results of the latest studies regarding it. The purpose is to help clinicians understand the problem across the board, so as to make the application of this class of drug correctly and the treatment of the disease suitably.
Liu
Ji-Hong
JH
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. hliu@tjh.tjmu.edu.cn
Wang
Tao
T
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000075202:Contraindications; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D010726:Phosphodiesterase Inhibitors